In a child losing immune cells through a leaky gut and lacking a functional thymus, daily thymosin injections produced only brief improvement — showing thymic peptides alone cannot replace a working thymus.
Thymus tissue: absent on biopsyWithout a functioning thymus, daily thymosin fraction 5 injections could not sustain immune recovery in this child
What the researchers found
The patient had primary intestinal lymphangiectasia (a condition where lymph vessels in the gut leak fluid, protein, and immune cells). Biopsies confirmed the diagnosis in her intestines, lungs, and lymph nodes. Lymphocytes were literally leaking out through her gut, confirmed by finding them in her stool.
Her thymus gland was essentially absent. A biopsy showed no thymic tissue. Blood tests showed very low or absent thymulin and thymosin alpha 1. She had a selective loss of T-cells, especially CD4+ helper T-cells.
Daily thymosin fraction 5 treatment produced a brief clinical improvement. But switching to weekly injections could not sustain it. Lymphocyte numbers never increased during treatment. The authors concluded that when the body loses T-cells faster than it can replace them, even thymic hormones cannot keep up without a functioning thymus.
Why it matters
This case showed a fundamental limit of thymic hormone therapy. Without a functioning thymus to produce new T-cells, thymic peptides alone cannot overcome ongoing lymphocyte loss. It highlighted that T-cell output and thymic structure are codependent.
How the study worked
Single patient case report. Immune workup included lymphocyte subpopulation analysis, proliferative responses to mitogens, NK cell function, and serum thymic hormone levels. Treatment was thymosin fraction 5, first daily then weekly. Biopsies of intestine, lung, lymph node, and thymus were performed.
What this study cannot tell us
This is a single case report. One patient's response cannot predict how others with similar conditions would respond. The thymosin dosing schedule was changed during treatment, making it hard to separate dose effects from disease progression.
How to read the evidence
Single case report — the lowest level of clinical evidence. Informative for hypothesis generation but cannot establish treatment efficacy.
When this study was published
Published in 1985. The understanding of thymic biology has advanced significantly, but the core finding — that thymic peptides need thymic tissue to work optimally — remains relevant.
The bigger picture
This case highlighted an important limitation of thymosin-based therapy: the peptides work best when there is still thymic tissue to respond to them. It raised questions about how to restore immune function when both the thymus gland and its hormonal signals are compromised — a challenge still relevant to aging and immunodeficiency research.
Questions still open
- Could higher or more frequent thymosin dosing have sustained the improvement?
- Would synthetic thymosin alpha 1 (rather than fraction 5) have been more effective?
- Can thymic tissue be regenerated or transplanted to restore T-cell production?
Common questions
What is intestinal lymphangiectasia?
Why didn't thymosin treatment work long-term?
Read the original research
Intestinal lymphangiectasia and thymic hypoplasia.
Clinical and experimental immunology, 59(1), 217-26
Citation
Sorensen, R U; Halpin, T C; Abramowsky, C R; Hornick, D L; Miller, K M; Naylor, P; Incefy, G S. (1985). Intestinal lymphangiectasia and thymic hypoplasia.. Clinical and experimental immunology, 59(1), 217-26.